Dr. Mark W. Ornstein

Internal Medicine
43 Main St, 
Farmingdale, NJ 
43 Main St, 
Farmingdale, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Ornstein is a primary care provider, practicing in Internal Medicine in Farmingdale, New Jersey. His top areas of expertise are Alzheimer's Disease, Dementia, Lafora Disease, and Unverricht-Lundborg Syndrome.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in NJ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

43 Main St, Farmingdale, NJ 07727

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drug: AL002
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
Enrollment Status: Terminated
Publish Date: November 17, 2022
Intervention Type: Radiation, Behavioral, Diagnostic test, Drug
Study Drug: Dihydrochloride Salt
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

1 Total Publications

Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.
Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.
Journal: Journal of neurology and neurosurgery
Published: December 26, 2017
Similar Doctors
Expertise in
33
conditions
Dr. Mark Lebwohl
Internal Medicine
Expertise in
33
conditions
Dr. Mark Lebwohl
Internal Medicine

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (42.5 miles away)
212-241-9728
Languages Spoken:
English
See accepted insurances

Mark Lebwohl is an Internal Medicine provider in New York, New York. Dr. Lebwohl is highly rated in 33 conditions, according to our data. His top areas of expertise are Plaque Psoriasis, Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP).

Expertise in
21
conditions
Dr. John Bilezikian
Internal Medicine
Expertise in
21
conditions
Dr. John Bilezikian
Internal Medicine

NewYork Presbyterian Columbia University Irving Medical Center

180 Fort Washington Ave, 
New York, NY 
 (46.1 miles away)
212-305-2663
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Bilezikian is an Internal Medicine provider in New York, New York. Dr. Bilezikian is highly rated in 21 conditions, according to our data. His top areas of expertise are Hyperparathyroidism, Hypoparathyroidism, Hypercalcemia, Parathyroidectomy, and Hormone Replacement Therapy (HRT).

Expertise in
62
conditions
Dr. Marco Tartaglia
Internal Medicine
Expertise in
62
conditions
Dr. Marco Tartaglia
Internal Medicine
20 Watsessing Ave, 
Bloomfield, NJ 
 (40.8 miles away)
973-364-0888
Languages Spoken:
English

Marco Tartaglia is a primary care provider, practicing in Internal Medicine in Bloomfield, New Jersey. Dr. Tartaglia is highly rated in 62 conditions, according to our data. His top areas of expertise are RASopathies, Noonan Syndrome, Cardiomyopathic Lentiginosis, and Rommen Mueller Sybert Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ornstein's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile